683
Views
5
CrossRef citations to date
0
Altmetric
Clinical Study

Ki-67 index as a prognostic factor of subsequent lapatinib-based therapy in HER2-positive metastatic breast cancer with resistance to trastuzumab

, , , , , , , , & show all
Pages 365-370 | Received 18 Jun 2013, Accepted 22 Dec 2013, Published online: 14 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Michela de Martino, Dazhong Zhuang, Tobias Klatte, Malte Rieken, Morgan Rouprêt, Evanguelos Xylinas, Thomas Clozel, Martin Krzywinski, Olivier Elemento & Shahrokh F Shariat. (2014) Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. Cancer Biology & Therapy 15:9, pages 1239-1247.
Read now

Articles from other publishers (4)

Bi-Cheng Wang, Bo-Ya Xiao, Ji-Quan Fan, Guo-He Lin, Chang Wang, Quentin Liu & Yan-Xia Zhao. (2021) 6 versus 12 months of adjuvant trastuzumab in HER2+ early breast cancer. Medicine 100:10, pages e24995.
Crossref
Doaa Tawfik, Angela Zaccagnino, Alexander Bernt, Monika Szczepanowski, Wolfram Klapper, Albrecht Schwab, Holger Kalthoff & Anna Trauzold. (2020) The A818–6 system as an in-vitro model for studying the role of the transportome in pancreatic cancer. BMC Cancer 20:1.
Crossref
Hiroyoshi Y. Tanaka & Mitsunobu R. Kano. 2019. Cancer Drug Delivery Systems Based on the Tumor Microenvironment. Cancer Drug Delivery Systems Based on the Tumor Microenvironment 57 89 .
Joshua L Hood, Hua Pan, Gregory M Lanza & Samuel A Wickline. (2009) Paracrine induction of endothelium by tumor exosomes. Laboratory Investigation 89:11, pages 1317-1328.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.